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Abstract 
Purpose: To evaluate antibacterial activity of a series of molecules bearing 1,3,4-oxadiazole and 
azomethine moieties.  
Methods: The 4-chlorobenzoic acid (1) was precursor to N'-substituted-2-(5-(4-chlorophenyl)-1,3,4-
oxadiazol-2-ylthio)acetohydrazide, 8a-p, through a multistep synthesis of corresponding ester, 2, 
hydrazide, 3 and 1,3,4-oxadiazole, 4. The molecule, 4, was subjected to electrophilic substitution by 
ethyl-2-bromoacetate to yield 5 which was stepped to 2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-
ylthio)acetohydrazide (6). The target molecules, 8a-p, were synthesized by nucleophilic addition of 6 to 
arylaldehydes, 7a-p. The proposed structures of all the synthesized molecules were elucidated by Infra 
Red (IR), Proton Nuclear Magnetic Resonance (1H-NMR) and Electron Impact Mass Spectrometry (EI-
MS) spectral data. Antibacterial activity was evaluated by the principle that microbial growth is in a log 
phase of growth and so results in increased absorbance of broth medium which is observed.  
Results: The molecule, 8b, was active against S. aureus and 8c against S. typhi only. The molecule, 
8p, was the most active against S. typhi with minimum inhibitory concentration (MIC) value of 10.04 ± 
1.25 µM while 8e was active against E. coli with MIC of 9.45 ± 1.00 µM, both relative to the reference 
standard, ciprofloxacin, which displayed MIC of 9.13 ± 2.00 and 8.90 ± 1.65 µM, respectively.  
Conclusion: Most of the synthesized molecules exhibit 50 % antibacterial activity relative to the 
reference. Molecules 8b and 8c are the least active compounds.  
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Bacteria have developed resistance to several 
antibiotics over time. Scientists have continued 
for several years to discover new potent 
molecules with remarkable activities [1]. 
Heterocyclic compounds have often been 
synthesized because of their broad spectrum of 
biological activities [2]. The 2,5-substituted-1,3,4-
oxadiazole derivatives, which have often been 
synthesized in the last decade, exhibit a number 
of biological activities [3-7] . In continuation of a 
previous synthetic work using 1,3,4-oxadiazole 
derivatives [8,9], N-substituted derivatives of 2-
(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-
ylthio)acetohydrazide have been synthesized in 
this study to determine their antibacterial 
potential.  
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Melting points of the synthesized compounds 
were carried out in a Griffin-George apparatus 
with open capillary tube and were uncorrected; 
I.R. spectral data by KBr pellet on a Jasco-320-A 
spectrophotometer; 1H-NMR spectral data by 
Bruker spectrometer in dimethylsulfoxide 
(DMSO) at 600 MHz; and EIMS spectral data by 
JMS-HX-110 spectrometer. Purity was verified 
via thin layer chromatography (TLC) on pre-
coated silica gel G-25-UV254 plates with ethyl 
acetateand n-hexane solvent systems. 
 
Synthesis of ethyl 4-chlorobenzoate (2) 
 
4-Chlorobenzoic acid (1; 5.0 g) was refluxed in 
20.0 mL absolute ethanol and 2.0 mL 
concentrated H2SO4 in a 250 mL round bottom 
(RB) flask for 3 h. After completion of the 
reaction which was verified by TLC, reaction 
mixture was taken up in a separating funnel 
followed by the addition of 200 mL distilled water 
and concentrated aqueous Na2CO3 solution (pH 
= 8-10). 50 mL diethylether was employed to 
extract the ester from the aqueous layer which 
was obtained on evaporation. 
 
Synthesis of 4-chlorobenzohydrazide (3) 
 
Ethyl 4-chlorobenzoate (2; 0.03 mol) was stirred 
with 2.0 mL 80 % hydrazine hydrate in 15.0 mL 
methanol in a 100 mL RB flask for 2 h. After final 
TLC, the product was precipitated out by the 
addition of excess cold distilled water, separated 





The mixture of 4-chlorobenzohydrazide (3; 0.03 
mol) and 50.0 mL absolute ethanol in a 250 mL 
RB flask was basified by KOH (0.03 mol) on 
reflux. Carbon disulfide (0.06 mol) was added at 
room temperature. The mixture was refluxed for 
5 h till single spot on TLC. Excess cold distilled 
water was poured into the reaction flask and 
acidified by dilute HCl (pH of 2-3). The 
precipitates were filtered and washed with 
distilled water. 
 
Synthesis of ethyl 2-(5-(4-chlorophenyl)-1,3,4-
oxadiazol-2-ylthio)acetate (5) 
 
The compound 4 (0.03 mol) was dissolved in 13 
mL DMF in a 50 mL RB flask. NaH (0.12 g) was 
added and stirred for 30 min. Ethyl 2-
bromoacetate (3.3 mL) was added and further 
stirred for 3.5 h. On single spot through TLC, 
excess ice cold distilled water was poured to 
flask for precipitation. The precipitates were 





The ester 5 (0.03 mol) in 20.0 mL methanol was 
stirred with 2.0 mL 80 % hydrazine hydrate 
strictly at room temperature in a 100 mL RB flask 
for 2.5 h. After complete reaction, the addition of 
excess cold distilled water resulted in 
precipitation. The product was separated by 






The compound 6 (0.001 mol) was taken in 17 mL 
methanol in a 50 mL RB flask followed by the 
addition of arylaldehydes (7a-p; 0.001 mol). The 
reaction mixture was stirred for 2 h. After 
complete reaction, the distilled water was added 
and the resulting precipitates were filtered, 
washed with distilled water and dried to afford 
the title compounds. 
 
Evaluation of antibacterial activity 
 
The antibacterial activity assay was executed as 
reported in the literature [10,11]. Antibacterial 
activity was performed in sterile 96-wells 
microplates under aseptic conditions. The 
variation in absorbance is noted which 
proportional to the microbial cell number is 
increasing in a log phase of growth. 
 
Statistical analysis  
 
All computations were executed in triplicate and 
statistical analysis was performed with Microsoft 
Excel 2010. The results are expressed as mean 
± SEM (n = 3). Minimum inhibitory concentration 
(MIC) was computed with suitable dilutions (5 - 
30 µg/well) for each sample and results 
calculated using EZ-Fit software (Perrella 




The target molecules, N'-substituted-2-(5-(4-
chlorophenyl)-1,3,4-oxadiazol-2-
ylthio)acetohydrazide (8a-p) were synthesized as 
shown in Scheme-1. The synthesized 
compounds were further evaluated for the 
antibacterial activity. 
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Comp.  -R Comp.  -R Comp. -R Comp.  -R 
8a H 8e 2-OH 8i 3- NO2 8m 2,3-OCH3  
8b 2-CH3 8f 3- OH 8j 4- NO2 8n 2,4-OCH3  
8c 3-CH3 8g 4- OH 8k 4-N(CH3)2 8o 2,5-OCH3 
8d 4-CH3 8h 2-NO2 8l 4-N(C2H5)2 8p 3,4-OCH3 
 
Scheme-1: Outline of synthesis of N’-substituted-2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetohydrazide 
(8a-p) 
 
Spectral characterization of synthesized 
molecules (2-6, 8a-p) 
 
Ethyl 4-chlorobenzoate (2) 
 
Yellow liquid; Yield: 84 %; Mol. formula: 
C9H9ClO2; Mol. mass: 184; IR (KBr, vmax/cm-1): 
3105, 1735, 1599, 697; 1H-NMR (600 MHz, 
DMSO, δ/ppm): 7.95 (d, J = 7.2 Hz, 2H, H-2' & 
H-6'), 7.63 (d, J = 8.4 Hz, 2H, H-3' & H-5'), 4.05 
(q, J = 7.2 Hz, 2H, -OCH2CH3), 1.10 (t, J = 7.2 
Hz, 3H, -OCH2CH3); EIMS (m/z): 186 [M+2]+, 




White amorphous solid; Yield: 78 %; M.P.: 162-
164 oC; Mol. formula: C7H7ClN2O; Mol. mass: 
170; IR (KBr, vmax/cm-1): 3328, 3118, 1657, 1609, 
703; 1H-NMR (600 MHz, DMSO, δ/ppm): 9.37 (s, 
1H, CONH), 8.76 (s, 2H, N-H), 7.89 (d, J = 7.8 
Hz, 2H, H-2' & H-6'), 7.59 (d, J = 7.8 Hz, 2H, H-3' 
& H-5'); EIMS (m/z): 172 [M+2]+, 170 [M]+, 139 




White amorphous solid; Yield: 86 %; M.P.: 170-
172 oC; Mol. formula: C8H5ClN2OS; Mol. mass: 
212; IR (KBr, vmax/cm-1): 3123, 1665, 1595, 707, 
615; 1H-NMR (600 MHz, DMSO, δ/ppm): 7.88 (d, 
J = 7.2 Hz, 2H, H-2' & H-6'), 7.63 (d, J = 8.4 Hz, 
2H, H-3' & H-5'); EIMS (m/z): 214 [M+2]+, 212 






White amorphous solid; Yield: 81 %; M.P.: 174-
176 oC; Mol. formula: C12H11ClN2O3S; Mol. mass: 
298; IR (KBr, vmax/cm-1): 3145, 1741, 1679, 1604, 
1058, 710; 1H-NMR (600 MHz, DMSO, δ/ppm): 
7.96 (d, J = 7.8 Hz, 2H, H-2' & H-6'), 7.69 (d, J = 
9.0 Hz, 2H, H-3' & H-5'), 4.64 (s, 2H, H-2''), 3.93 
(q, J = 7.2 Hz, 2H, -OCH2CH3), 1.03 (t, J = 7.2 
Hz, 3H, -OCH2CH3); EIMS (m/z): 300 [M+2]+, 
298 [M]+, 225 [C9H6ClN2OS]+, 179 [C8H4ClN2O]+, 





White amorphous solid; Yield: 87 %; M.P.: 178-
180 oC; Mol. formula: C10H9ClN4O2S; Mol. mass: 
284; IR (KBr, vmax/cm-1): 3378, 3085, 1661, 1681, 
1601, 1065, 703; 1H-NMR (600 MHz, DMSO, 
δ/ppm): 9.41 (s, 1H, CONH), 8.84 (s, 2H, N-H), 
7.97 (d, J = 7.8 Hz, 2H, H-2' & H-6'), 7.67 (d, J = 
9.0 Hz, 2H, H-3' & H-5'), 4.61 (s, 2H, H-2''); EIMS 
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(m/z): 286 [M+2]+, 284 [M]+, 225 [C9H6ClN2OS]+, 
179 [C8H4ClN2O]+, 139 [C7H4ClO]+, 137 





White amorphous solid; Yield: 73 %; M.P.: 160-
162 oC; Mol. formula: C17H13ClN4O2S; Mol. mass: 
372; IR (KBr, vmax/cm-1): 3048, 1659, 1609, 1071, 
690; 1H-NMR (600 MHz, DMSO, δ/ppm): 11.79 
(s, 1H, CONH), 8.22 (s, 1H, H-7'''), 7.97 (d, J = 
8.4 Hz, 2H, H-2' & H-6'), 7.70 (dd, J = 7.2, 1.8 
Hz, 2H, H-2''' & H-6'''), 7.65 (d, J = 9.0 Hz, 2H, H-
3' & H-5'), 7.47-7.43 (m, 3H, H-3''' to H-5'''), 4.67 
(s, 2H, H-2''); EIMS (m/z): 374 [M+2]+, 372 [M]+, 
225 [C9H6ClN2OS]+, 179 [C8H4ClN2O]+, 147 







White amorphous solid; Yield: 79 %; M.P.: 166-
168 oC; Mol. formula: C18H15ClN4O2S; Mol. mass: 
386; IR (KBr, vmax/cm-1): 3063, 1651, 1615, 1074, 
699; 1H-NMR (600 MHz, DMSO, δ/ppm): 11.72 
(s, 1H, CONH), 8.31 (s, 1H, H-7'''), 7.97 (d, J = 
8.4 Hz, 2H, H-2' & H-6'), 7.75 (dd, J = 9.0, 1.8 
Hz, 1H, H-6'''), 7.65 (d, J = 9.0 Hz, 2H, H-3' & H-
5'), 7.35-7.30 (m, 2H, H-4''' & H-5'''), 7.26 (d, J = 
7.2 Hz, 1H, H-3'''), 4.67 (s, 2H, H-2''), 2.44 (s, 
3H, CH3-2'''); EIMS (m/z): 388 [M+2]+, 386 [M]+, 
225 [C9H6ClN2OS]+, 179 [C8H4ClN2O]+, 161 







White amorphous solid; Yield: 80 %; M.P.: 162-
164 oC; Mol. formula: C18H15ClN4O2S; Mol. mass: 
386; IR (KBr, vmax/cm-1): 3056, 1676, 1602, 1047, 
696; 1H-NMR (600 MHz, DMSO, δ/ppm): 11.75 
(s, 1H, CONH), 8.16 (s, 1H, H-7'''), 7.95 (d, J = 
9.0 Hz, 2H, H-2' & H-6'), 7.63 (d, J = 8.4 Hz, 2H, 
H-3' & H-5'), 7.48 (d, J = 7.2 Hz, 1H, H-6'''), 7.32 
(t, J = 7.8 Hz, 1H, H-5'''), 7.26 (s, 1H, H-2'''), 7.23 
(d, J = 7.2 Hz, 1H, H-4'''), 4.66 (s, 2H, H-2''), 2.33 
(s, 3H, CH3-3'''); EIMS (m/z): 388 [M+2]+, 386 
[M]+, 225 [C9H6ClN2OS]+, 179 [C8H4ClN2O]+, 161 







White amorphous solid; Yield: 78 %; M.P.: 170-
172 oC; Mol. formula: C18H15ClN4O2S; Mol. mass: 
386; IR (KBr, vmax/cm-1): 3046, 1665, 1619, 1056, 
692; 1H-NMR (600 MHz, DMSO, δ/ppm): 11.72 
(s, 1H, CONH), 8.18 (s, 1H, H-7'''), 7.96 (d, J = 
8.4 Hz, 2H, H-2' & H-6'), 7.64 (d, J = 8.4 Hz, 2H, 
H-3' & H-5'), 7.58 (d, J = 7.8 Hz, 2H, H-2''' & H-
6'''), 7.24 (d, J = 7.8 Hz, 2H, H-3''' & H-5'''), 4.65 
(s, 2H, H-2''), 2.34 (s, 3H, CH3-4'''); EIMS (m/z): 
388 [M+2]+, 386 [M]+, 225 [C9H6ClN2OS]+, 179 
[C8H4ClN2O]+, 161 [C9H9N2O]+, 139 [C7H4ClO]+, 






Dirty white amorphous solid; Yield: 87 %; M.P.: 
212-214 oC; Mol. formula: C17H13ClN4O3S; Mol. 
mass: 388; IR (KBr, vmax/cm-1): 3064, 1678, 
1611, 1061, 688; 1H-NMR (600 MHz, DMSO, 
δ/ppm): 11.73 (s, 1H, CONH), 8.35 (s, 1H, H-7'''), 
7.97 (d, J = 9.0 Hz, 2H, H-2' & H-6'), 7.71 (dd, J 
= 7.8, 1.8 Hz, 1H, H-6'''), 7.65 (d, J = 8.4 Hz, 2H, 
H-3' & H-5'), 7.56 (dd, J = 7.2, 1.2 Hz, 1H, H-3'''), 
7.25 (ddd, J = 7.2, 1.8 Hz, 1H, H-4'''), 6.85 (t, J = 
7.2 Hz, 1H, H-5'''), 4.66 (s, 2H, H-2''); EIMS 
(m/z): 390 [M+2]+, 388 [M]+, 225 [C9H6ClN2OS]+, 
179 [C8H4ClN2O]+, 163 [C8H7N2O2]+, 139 






White amorphous solid; Yield: 82 %; M.P.: 218-
220 oC; Mol. formula: C17H13ClN4O3S; Mol. mass: 
388; IR (KBr, vmax/cm-1): 3035, 1679, 1612, 1072, 
698; 1H-NMR (600 MHz, DMSO, δ/ppm): 11.74 
(s, 1H, CONH), 9.64 (s, 1H, HO-3'''), 8.12 (s, 1H, 
H-7'''), 7.97 (d, J = 7.8 Hz, 2H, H-2' & H-6'), 7.65 
(d, J = 9.0 Hz, 2H, H-3' & H-5'), 7.24 (t, J = 7.8 
Hz, 1H, H-5'''), 7.15 (s, 1H, H-2'''), 7.09 (d, J = 
7.8 Hz, 1H, H-6'''), 6.83 (dd, J = 7.8, 2.4 Hz, 1H, 
H-4'''), 4.66 (s, 2H, H-2''); EIMS (m/z): 390 
[M+2]+, 388 [M]+, 225 [C9H6ClN2OS]+, 179 
[C8H4ClN2O]+, 163 [C8H7N2O2]+, 139 [C7H4ClO]+, 






White amorphous solid; Yield: 77 %; M.P.: 234-
236 oC; Mol. formula: C17H13ClN4O3S; Mol. mass: 
Rasool et al 
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388; IR (KBr, vmax/cm-1): 3039, 1674, 1601, 1078, 
704; 1H-NMR (600 MHz, DMSO, δ/ppm): 11.74 
(s, 1H, CONH), 8.09 (s, 1H, H-7'''), 7.96 (d, J = 
8.4 Hz, 2H, H-2' & H-6'), 7.64 (d, J = 8.4 Hz, 2H, 
H-3' & H-5'), 7.52 (d, J = 9.0 Hz, 2H, H-2''' & H-
6'''), 6.80 (d, J = 9.0 Hz, 2H, H-3''' & H-5'''), 4.62 
(s, 2H, H-2''); EIMS (m/z): 390 [M+2]+, 388 [M]+, 
225 [C9H6ClN2OS]+, 179 [C8H4ClN2O]+, 163 






Yellow amorphous solid; Yield: 73 %; M.P.: 212-
214 oC; Mol. formula: C17H12ClN5O4S; Mol. mass: 
417; IR (KBr, vmax/cm-1): 3084, 1673, 1613, 1066, 
701; 1H-NMR (600 MHz, DMSO, δ/ppm): 12.09 
(s, 1H, CONH), 8.33 (s, 1H, H-7'''), 8.30 (d, J = 
9.0 Hz, 1H, H-6'''), 8.26 (d, J = 9.0 Hz, 2H, H-2' & 
H-6'), 7.98 (dd, J = 9.0, 2.4 Hz, 1H, H-3'''), 7.97-
7.95 (m, 2H, H-4''' & H-5'''), 7.65 (d, J = 8.4 Hz, 
2H, H-3' & H-5'), 4.70 (s, 2H, H-2''); EIMS (m/z): 
419 [M+2]+, 417 [M]+, 225 [C9H6ClN2OS]+, 192 
[C8H6N3O3]+, 179 [C8H4ClN2O]+, 139 [C7H4ClO]+, 





White amorphous solid; Yield: 76 %; M.P.: 222-
224 oC; Mol. formula: C17H12ClN5O4S; Mol. mass: 
417; IR (KBr, vmax/cm-1): 3075, 1651, 1606, 1057, 
693; 1H-NMR (600 MHz, DMSO, δ/ppm): 12.05 
(s, 1H, CONH), 8.52 (t, J = 1.8 Hz, 1H, H-2'''), 
8.36 (s, 1H, H-7'''), 8.26 (dd, J = 9.0, 1.8 Hz, 1H, 
H-6'''), 8.16 (d, J = 7.8 Hz, 1H, H-4'''), 7.96 (d, J = 
9.0 Hz, 2H, H-2' & H-6'), 7.74 (t, J = 8.4 Hz, 1H, 
H-5'''), 7.65 (d, J = 8.4 Hz, 2H, H-3' & H-5'), 4.72 
(s, 2H, H-2''); EIMS (m/z): 419 [M+2]+, 417 [M]+, 
225 [C9H6ClN2OS]+, 192 [C8H6N3O3]+, 179 




1,3,4-oxadiazol-2-ylthio)acetohydrazide (8j)  
 
Yellow amorphous solid; Yield: 75 %; M.P.: 240-
242 oC; Mol. formula: C17H12ClN5O4S; Mol. mass: 
417; IR (KBr, vmax/cm-1): 3081, 1659, 1619, 1069, 
691; 1H-NMR (600 MHz, DMSO, δ/ppm): 12.08 
(s, 1H, CONH), 8.43 (s, 1H, H-7'''), 8.09 (d, J = 
7.8 Hz, 2H, H-3''' & H-5'''), 8.05 (d, J = 9.6 Hz, 
2H, H-2''' & H-6'''), 7.96 (d, J = 7.8 Hz, 2H, H-2' & 
H-6'), 7.66 (d, J = 9.0 Hz, 2H, H-3' & H-5'), 4.67 
(s, 2H, H-2''); EIMS (m/z): 419 [M+2]+, 417 [M]+, 
225 [C9H6ClN2OS]+, 192 [C8H6N3O3]+, 179 







Yellow amorphous solid; Yield: 71 %; M.P.: 170-
172 oC; Mol. formula: C19H18ClN5O2S; Mol. mass: 
415; IR (KBr, vmax/cm-1): 3043, 1679, 1617, 1064, 
701; 1H-NMR (600 MHz, DMSO, δ/ppm): 11.48 
(s, 1H, CONH), 8.04 (s, 1H, H-7'''), 7.96 (d, J = 
9.0 Hz, 2H, H-2' & H-6'), 7.63 (d, J = 8.4 Hz, 2H, 
H-3' & H-5'), 7.47 (d, J = 8.4 Hz, 2H, H-2''' & H-
6'''), 6.69 (d, J = 9.0 Hz, 2H, H-3''' & H-5'''), 4.59 
(s, 2H, H-2''), 2.96 (s, 6H, (CH3)2N-4'''); EIMS 
(m/z): 417 [M+2]+, 415 [M]+, 225 [C9H6ClN2OS]+, 
190 [C10H12N3O]+, 179 [C8H4ClN2O]+, 139 






Yellow amorphous solid; Yield: 79 %; M.P.: 174-
176 oC; Mol. formula: C21H22ClN5O2S; Mol. mass: 
443; IR (KBr, vmax/cm-1): 3058, 1634, 1610, 1059, 
689; 1H-NMR (600 MHz, DMSO, δ/ppm): 11.45 
(s, 1H, CONH), 8.01 (s, 1H, H-7'''), 7.96 (d, J = 
9.0 Hz, 2H, H-2' & H-6'), 7.63 (d, J = 8.4 Hz, 2H, 
H-3' & H-5'), 7.44 (d, J = 8.4 Hz, 2H, H-2''' & H-
6'''), 6.64 (d, J = 9.0 Hz, 2H, H-3''' & H-5'''), 4.58 
(s, 2H, H-2''), 2.60 (q, J = 7.2 Hz, 4H, 
(CH3CH2)2N-4'''), 1.09 (t, J = 7.2 Hz, 6H, 
(CH3CH2)2N-4'''); EIMS (m/z): 445 [M+2]+, 443 
[M]+, 225 [C9H6ClN2OS]+, 212 [C8H5ClN2OS]+, 
190 [C11H16N3]+, 179 [C8H4ClN2O]+, 139 






White amorphous solid; Yield: 83 %; M.P.: 164-
166 oC; Mol. formula: C19H17ClN4O4S; Mol. mass: 
432; IR (KBr, vmax/cm-1): 3067, 1633, 1602, 1055, 
708; 1H-NMR (600 MHz, DMSO, δ/ppm): 11.73 
(s, 1H, CONH), 8.32 (s, 1H, H-7'''), 7.96 (d, J = 
9.0 Hz, 2H, H-2' & H-6'), 7.64 (d, J = 9.0 Hz, 2H, 
H-3' & H-5'), 7.55 (d, J = 8.4 Hz, 1H, H-6'''), 7.43 
(dd, J = 7.8, 1.8 Hz, 1H, H-4'''), 7.11 (t, J = 7.8 
Hz, 1H, H-5'''), 4.65 (s, 2H, H-2''), 3.84 (s, 3H, 
CH3O-3'''), 3.77 (s, 3H, CH3O-2'''); EIMS (m/z): 
434 [M+2]+, 432 [M]+, 225 [C9H6ClN2OS]+, 179 
[C8H4ClN2O]+, 139 [C7H4ClO]+, 137 [C7H4ClN]+, 
111 [C6H4Cl]+. 
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White amorphous solid; Yield: 85 %; M.P.: 166-
168 oC; Mol. formula: C19H17ClN4O4S; Mol. mass: 
432; IR (KBr, vmax/cm-1): 3061, 1643, 1604, 1058, 
699; 1H-NMR (600 MHz, DMSO, δ/ppm): 11.61 
(s, 1H, CONH), 8.27 (s, 1H, H-7'''), 7.96 (d, J = 
9.0 Hz, 2H, H-2' & H-6'), 7.73 (d, J = 8.4 Hz, 1H, 
H-6'''), 7.65 (d, J = 9.0 Hz, 2H, H-3' & H-5'), 6.62 
(d, J = 2.4 Hz, 1H, H-3'''), 6.57 (dd, J = 8.4, 1.8 
Hz, 1H, H-5'''), 4.61 (s, 2H, H-2''), 3.85 (s, 3H, 
CH3O-2'''), 3.82 (s, 3H, CH3O-4'''); EIMS (m/z): 
434 [M+2]+, 432 [M]+, 225 [C9H6ClN2OS]+, 179 







Dirty white amorphous solid; Yield: 80 %; M.P.: 
174-176 oC; Mol. formula: C19H17ClN4O4S; Mol. 
mass: 432; IR (KBr, vmax/cm-1): 3085, 1631, 
1608, 1053, 696; 1H-NMR (600 MHz, DMSO, 
δ/ppm): 11.73 (s, 1H, CONH), 8.33 (s, 1H, H-7'''), 
7.96 (d, J = 8.4 Hz, 2H, H-2' & H-6'), 7.64 (d, J = 
9.0 Hz, 2H, H-3' & H-5'), 7.36 (d, J = 3.0 Hz, 1H, 
H-6'''), 7.05 (d, J = 7.8 Hz, 1H, H-3'''), 7.01 (dd, J 
= 9.0, 3.0 Hz, 1H, H-4'''), 4.66 (s, 2H, H-2''), 3.80 
(s, 3H, CH3O-5'''), 3.75 (s, 3H, CH3O-2'''); EIMS 
(m/z): 434 [M+2]+, 432 [M]+, 225 [C9H6ClN2OS]+, 
179 [C8H4ClN2O]+, 139 [C7H4ClO]+, 137 






White amorphous solid; Yield: 84 %; M.P.: 162-
164 oC; Mol. formula: C19H17ClN4O4S; Mol. mass: 
432; IR (KBr, vmax/cm-1): 3078, 1689, 1605, 1059, 
711; 1H-NMR (600 MHz, DMSO, δ/ppm): 11.69 
(s, 1H, CONH), 8.12 (s, 1H, H-7'''), 7.94 (d, J = 
9.0 Hz, 2H, H-2' & H-6'), 7.63 (d, J = 9.0 Hz, 2H, 
H-3' & H-5'), 7.31 (d, J = 1.8 Hz, 1H, H-2'''), 7.18 
(dd, J = 8.4, 1.8 Hz, 1H, H-6'''), 6.98 (d, J = 8.4 
Hz, 1H, H-5'''), 4.64 (s, 2H, H-2''), 3.80 (s, 3H, 
CH3O-3'''), 3.79 (s, 3H, CH3O-4'''); EIMS (m/z): 
434 [M+2]+, 432 [M]+, 225 [C9H6ClN2OS]+, 179 
[C8H4ClN2O]+, 139 [C7H4ClO]+, 137 [C7H4ClN]+, 
111 [C6H4Cl]+. 
 
Antibacterial activity  
 
The results of antibacterial activity results are 
shown in Tables 1 and 2. 
 
 




S. typhi (-) E. coli (-) P. aeroginosa (-) B. subtilis (+) S. aureus (+) 
6 76.62±2.00 81.16±1.79 68.04±1.65 64.23±3.06 64.55±2.55 
8a 62.79±3.65 58.53±1.42 43.56±1.98 51.95±1.75 43.75±2.35 
8b 48.58±1.06 43.53±2.53 20.05±2.84 38.18±2.23 56.70±3.70 
8c 53.92±2.13 49.32±2.58 38.76±1.72 46.59±1.77 47.35±3.05 
8d 60.64±2.22 57.63±2.14 28.97±5.00 53.23±2.41 56.45±1.55 
8e 82.89±2.25 79.84±2.43 76.75±1.60 78.77±2.41 71.45±4.15 
8f 69.95±2.87 72.16±1.36 51.60±3.76 58.05±1.79 52.00±1.70 
8g 65.59±1.77 53.21±2.16 59.74±0.67 54.18±1.06 66.55±3.45 
8h 51.86±3.05 50.63±2.77 51.86±1.75 51.09±1.94 45.60±5.00 
8i 54.75±1.55 51.16±4.36 45.88±2.47 53.64±2.59 63.30±4.30 
8j 75.25±1.40 74.05±2.49 65.36±1.44 66.55±3.76 70.55±0.65 
8k 67.45±1.67 61.74±1.64 53.25±2.01 60.86±2.95 58.10±1.00 
8l 64.90±1.32 71.11±2.23 59.02±2.32 57.50±1.18 59.60±2.60 
8m 67.65±3.22 64.95±1.33 52.16±3.61 53.09±2.55 56.60±4.30 
8n 69.56±1.76 69.16±2.09 55.10±0.15 60.05±1.34 60.95±0.35 
8o 75.05±2.08 67.74±2.11 57.73±1.00 60.59±3.14 57.50±2.20 
8p 66.76±1.67 60.63±1.88 46.44±1.70 52.14±3.22 55.55±3.35 
Ciprofloxacin 91.83±0.05 91.65±1.47 90.56±1.11 90.89±1.05 92.05±2.32 
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Table 2: Antibacterial activity (MIC) of the synthesized compounds 
  
Compound MIC (µM) S. typhi (-) E. coli (-) P. aeroginosa (-) B. subtilis (+) S. aureus (+) 
6 11.23±2.08 13.52±2.40 13.49±3.08 13.35±5.00 16.18±1.15 
8a 10.37±2.13 13.46±2.50 - 17.54±1.50 - 
8b - - - - 16.51±2.50 
8c 18.21±4.83 - - - - 
8d 14.29±3.67 16.58±5.00 - 13.59±1.94 16.40±1.15 
8e 12.03±4.92 9.45±1.00 10.53±2.97 11.94±5.00 10.65±3.43 
8f 10.32±1.42 11.21±1.60 18.52±3.46 14.67±0.55 19.09±1.38 
8g 12.93±3.00 13.18±4.07 15.47±1.23 15.44±5.00 13.37±5.00 
8h 19.08±5.00 19.66±4.00 19.02±4.08 19.69±1.38 - 
8i 17.64±5.00 16.32±1.20 - 15.45±4.37 12.13±5.00 
8j 14.26±5.00 12.03±4.13 12.42±1.85 14.68±2.16 10.98±2.64 
8k 14.15±0.42 15.36±2.67 18.13±1.12 14.40±3.81 14.15±4.63 
8l 17.00±1.87 14.02±5.00 17.68±4.62 16.73±4.75 16.03±3.38 
8m 11.41±1.25 12.02±1.87 18.44±3.11 14.41±2.31 15.18±2.38 
8n 10.92±1.67 12.76±1.33 15.43±1.46 12.71±4.13 14.31±3.00 
8o 12.10±1.00 13.44±4.67 14.91±3.00 11.01±3.94 16.01±5.00 
8p 10.04±1.25 11.90±4.20 - 18.10±2.00 17.90±4.00 




The compound, 8a, showed characteristic 
absorption bands of the IR spectra at 3048, 
1659, 1609, 1071 and 690. Its molecular formula, 
C17H13ClN4O2S was shown by EIMS with [M]+ 
peak at m/z 372 and number of protons in 1H-
NMR spectrum. The prominent fragmentation 
peaks of this molecule were depicted in Fig. 1. 
The three signals in 1H-NMR spectrum allotted to 
six protons of benzylidene moiety were δ 8.22 
(1H, H-7'''), δ 7.70 (J = 7.2, 1.8 Hz, 2H, H-2''' & 
H-6''') and δ 7.47-7.43 (3H, H-3''' to H-5'''). Two 
doublets at δ 7.97 with J = 8.4 Hz and at δ 7.65 
with J = 9.0 Hz were assigned to H-2' & H-6' and 
H-3' & H-5', respectively. The signals resonating 
at δ 11.79 (s, 1H, CONH) and 4.67 (s, 2H, H-2'') 
confirmed the acetamidic protons.  
 
On the basis of spectral analysis, the molecule 
8a was named, N'-benzylidene-2-(5-(4-
chlorophenyl)-1,3,4-oxadiazol-2-
ylthio)acetohydrazide. The structures of other 














[M]+ m/z = 372
m/z = 147m/z = 253
m/z = 225 m/z = 119
m/z = 91
N CH
























Figure 1: Mass fragmentation pattern of synthesized molecule 8a 
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The activities of synthesized molecules were 
found to be higher against various bacterial 
strains of gram negative bacteria as compared to 
such type of other molecules [12-15]. The 
methylbenzylidenes (8b, 8c & 8d) and 
nitrobenzylidene (8h, 8i & 8j) showed the least 
activities except for p-substituted. Overall 8a, 8b, 
8c, 8d, 8h, 8i and 8p executed a little low activity 
against some of bacterial strains. Among Gram-
negative bacterial strains, 8p was the most active 
against S. typhi with MIC value of 10.04 ± 1.25 
µM relative to the reference standard, 
ciprofloxacin with MIC value of 9.13 ± 2.00 µM 
and 8e against E. coli with MIC value of 9.45 ± 
1.00 µM relative to 8.90 ± 1.65 µM. The potent 
activities of 8p and 8e may be due to 3,4-





The relatively moderate MIC values indicate that 
the synthesized molecules possess potentials as 
antibacterial agents but there is need for further 
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